FCGR2B and neoplasm: Anti-CD25 antibodies exhausted the peripheral Tregs, and the upregulation of inhibitory FcγR IIb at the tumor area prevented the depletion of intra-tumoral Tregs, which may be the reason for the lack of anti-tumor activity previously observed in preclinical models.